Abzena PLC?provides a suite of complementary services and technologies to R&D organizations to improve the chances of successful development of therapeutic proteins and antibodies, The company is expected to capitalize on the growth of the biopharmaceutical market. Abzena has significant know-how, supported by a broad patent estate, to enable it to create better biopharmaceuticals for its customers.
Abzena operates a balanced business model with growing revenues from its service business and the potential for significant future growth through royalty bearing licences for the application of its technologies to biopharmaceutical products. The Group?s technologies and services are provided through its wholly-owned subsidiaries, PolyTherics?and Antitope.
PolyTherics and Antitope have been developing and offering their technologies and services for over 10 years and their scientists have provided expertise to a wide range of companies, including most of the top 20 biopharmaceutical companies, many large and small public and private biotech, and academic groups, across the world.
Babraham
Cambridge CB22 3AT
United Kingdom
Web:?Abzena
